DK3463345T3 - Farmaceutiske kombinationer - Google Patents
Farmaceutiske kombinationer Download PDFInfo
- Publication number
- DK3463345T3 DK3463345T3 DK17807555.2T DK17807555T DK3463345T3 DK 3463345 T3 DK3463345 T3 DK 3463345T3 DK 17807555 T DK17807555 T DK 17807555T DK 3463345 T3 DK3463345 T3 DK 3463345T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical combinations
- pharmaceutical
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662345389P | 2016-06-03 | 2016-06-03 | |
PCT/US2017/035653 WO2017210538A1 (en) | 2016-06-03 | 2017-06-02 | Pharmaceutical combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3463345T3 true DK3463345T3 (da) | 2023-01-09 |
Family
ID=60477982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17807555.2T DK3463345T3 (da) | 2016-06-03 | 2017-06-02 | Farmaceutiske kombinationer |
Country Status (26)
Country | Link |
---|---|
US (3) | US10485788B2 (da) |
EP (1) | EP3463345B1 (da) |
JP (2) | JP6805336B2 (da) |
KR (1) | KR102439911B1 (da) |
CN (1) | CN109890386B (da) |
AU (1) | AU2017275650B2 (da) |
BR (1) | BR112018074941A2 (da) |
CA (1) | CA3026361A1 (da) |
CL (1) | CL2018003421A1 (da) |
CO (1) | CO2019000010A2 (da) |
CR (1) | CR20190002A (da) |
DK (1) | DK3463345T3 (da) |
FI (1) | FI3463345T3 (da) |
HU (1) | HUE060653T2 (da) |
IL (1) | IL263431A (da) |
MA (1) | MA45187A (da) |
MX (1) | MX2018014973A (da) |
PH (1) | PH12018502549A1 (da) |
PL (1) | PL3463345T3 (da) |
PT (1) | PT3463345T (da) |
RU (1) | RU2759669C2 (da) |
SG (1) | SG11201810793XA (da) |
SI (1) | SI3463345T1 (da) |
UA (1) | UA125436C2 (da) |
WO (1) | WO2017210538A1 (da) |
ZA (1) | ZA201900019B (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201810793XA (en) | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
US10973829B2 (en) * | 2016-09-19 | 2021-04-13 | Novartis Ag | Therapeutic uses of a C-RAF inhibitor |
CA3150474A1 (en) * | 2019-10-11 | 2021-04-15 | Geraint Iwan Davies | DRUG DOSAGE DETERMINATION DEVICES AND METHODS |
EP4103286A4 (en) * | 2020-02-10 | 2024-03-20 | Cedars Sinai Medical Center | METHOD FOR TREATING PANCREATIC CANCER |
JP7288220B2 (ja) | 2021-03-29 | 2023-06-07 | ダイキン工業株式会社 | モータ、送風装置、および冷凍装置 |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
SG148857A1 (en) | 2002-03-13 | 2009-01-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
MX2011000738A (es) | 2008-07-24 | 2011-02-23 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inhibidoers de proteina cinasa. |
JP5527878B2 (ja) * | 2009-07-30 | 2014-06-25 | トムソン ライセンシング | 表示装置及び音声出力装置 |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
WO2012170715A1 (en) * | 2011-06-07 | 2012-12-13 | Caris Mpi, Inc. | Molecular profiling for cancer |
CA2855243C (en) * | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
CN105708819B (zh) | 2011-11-23 | 2020-12-29 | 诺华股份有限公司 | 医药制剂 |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
PT2882440T (pt) | 2012-08-07 | 2019-04-23 | Array Biopharma Inc | Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa |
LT3702351T (lt) | 2012-10-19 | 2024-01-10 | Array Biopharma, Inc. | Kompozicijos, apimančios mek inhibitorių |
BR112015009134A2 (pt) * | 2012-10-25 | 2017-07-04 | Glaxosmithkline Llc | combinação |
SG10201906270VA (en) | 2013-03-21 | 2019-08-27 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
US9447013B2 (en) * | 2013-07-18 | 2016-09-20 | Daicel Corporation | Method for producing oxide |
US20150087279A1 (en) * | 2013-09-20 | 2015-03-26 | Better Mousetrap, LLC | Mobile accident processing system and method |
WO2015087279A1 (en) * | 2013-12-12 | 2015-06-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
WO2016155670A1 (zh) * | 2015-04-01 | 2016-10-06 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
WO2017019279A1 (en) | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
SG11201810793XA (en) | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
-
2017
- 2017-06-02 SG SG11201810793XA patent/SG11201810793XA/en unknown
- 2017-06-02 SI SI201731293T patent/SI3463345T1/sl unknown
- 2017-06-02 CN CN201780048857.2A patent/CN109890386B/zh active Active
- 2017-06-02 BR BR112018074941-9A patent/BR112018074941A2/pt active Search and Examination
- 2017-06-02 CA CA3026361A patent/CA3026361A1/en active Pending
- 2017-06-02 WO PCT/US2017/035653 patent/WO2017210538A1/en unknown
- 2017-06-02 AU AU2017275650A patent/AU2017275650B2/en active Active
- 2017-06-02 UA UAA201813074A patent/UA125436C2/uk unknown
- 2017-06-02 KR KR1020187037798A patent/KR102439911B1/ko active IP Right Grant
- 2017-06-02 MA MA045187A patent/MA45187A/fr unknown
- 2017-06-02 CR CR20190002A patent/CR20190002A/es unknown
- 2017-06-02 HU HUE17807555A patent/HUE060653T2/hu unknown
- 2017-06-02 RU RU2018146812A patent/RU2759669C2/ru active
- 2017-06-02 MX MX2018014973A patent/MX2018014973A/es unknown
- 2017-06-02 JP JP2019515782A patent/JP6805336B2/ja active Active
- 2017-06-02 PT PT178075552T patent/PT3463345T/pt unknown
- 2017-06-02 PL PL17807555.2T patent/PL3463345T3/pl unknown
- 2017-06-02 FI FIEP17807555.2T patent/FI3463345T3/fi active
- 2017-06-02 EP EP17807555.2A patent/EP3463345B1/en not_active Revoked
- 2017-06-02 DK DK17807555.2T patent/DK3463345T3/da active
-
2018
- 2018-11-30 CL CL2018003421A patent/CL2018003421A1/es unknown
- 2018-12-03 US US16/208,172 patent/US10485788B2/en active Active
- 2018-12-03 PH PH12018502549A patent/PH12018502549A1/en unknown
- 2018-12-03 IL IL263431A patent/IL263431A/en unknown
-
2019
- 2019-01-02 ZA ZA2019/00019A patent/ZA201900019B/en unknown
- 2019-01-02 CO CONC2019/0000010A patent/CO2019000010A2/es unknown
- 2019-09-24 US US16/580,505 patent/US11376239B2/en active Active
-
2020
- 2020-12-03 JP JP2020201152A patent/JP2021054832A/ja active Pending
-
2022
- 2022-05-16 US US17/745,136 patent/US20230044943A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3405050T3 (da) | Børnesikret snusbeholder | |
DK3436823T3 (da) | Antigen-array | |
DK3529240T3 (da) | Farmaceutiske forbindelser | |
DK3445708T3 (da) | Stigbøjle | |
DK3402792T3 (da) | Quinolin-2-on-derivater | |
DK3335532T3 (da) | Tandharve | |
DK3509963T3 (da) | Pallecontainer | |
DK3463345T3 (da) | Farmaceutiske kombinationer | |
ES2841649T5 (es) | Composición farmacéutica | |
DK3528829T3 (da) | Bacitracin-alginat-oligomer-konjugater | |
DK3575238T3 (da) | Pallecontainer | |
DE112017006386A5 (de) | Schraubarbeitszylinder | |
DE112017000734A5 (de) | Glycolsensor | |
DK3471535T3 (da) | Dyrelift | |
DK3323708T3 (da) | Bovfender | |
DK3452590T3 (da) | Plademagnet | |
DK3452587T3 (da) | Penicillin-g-acylaser | |
DK3295800T3 (da) | Sandwichkiksindretning | |
DK3288967T3 (da) | Farmaceutisk forbindelse | |
DE112017006474A5 (de) | Gargerätevorrichtung | |
DK3551954T3 (da) | Rekuperator | |
DE112017005767A5 (de) | Nasslaufende lamellenkupplung | |
DK3468607T3 (da) | Resveratrolsolubilisat | |
DK3430609T3 (da) | Smartflag | |
DE112017000296A5 (de) | Radgeschwindigkeitssensorvorrichtung |